Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines

Robert I. Haddad, Christian Nasr, Lindsay Bischoff, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan Yang Duh, Hormoz Ehya, Whitney Goldner, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Bryan McIver, Christopher D. Raeburn, John A. RidgeMatthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Rebecca Sippel, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Alyse Johnson-Chilla, Karin G. Hoffmann, Lisa A. Gurski

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.

Original languageEnglish (US)
Pages (from-to)1429-1440
Number of pages12
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2018

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this